Comparative Pharmacology
Head-to-head clinical analysis: ALKERGOT versus MAXALT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERGOT versus MAXALT.
ALKERGOT vs MAXALT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine tartrate acts as a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also blocks alpha-adrenergic receptors. It causes vasoconstriction of intracranial blood vessels and reduces extravasation of plasma proteins, thereby alleviating migraine pain. Caffeine enhances ergotamine absorption and may provide additional vasoconstrictive effects.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve signaling.
Oral: Ergotamine 1mg/caffeine 100mg combination: 2 tablets at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
5 mg or 10 mg orally at onset of migraine; maximum 30 mg in 24 hours (two doses with at least 2 hours between them).
None Documented
None Documented
Terminal elimination half-life is 2–4 hours. Clinical context: Short half-life supports use for acute migraine attacks; frequent dosing may be needed for prolonged symptoms.
2-3 hours in plasma; clinical effect correlates with distribution to CNS rather than plasma half-life.
Primarily hepatic metabolism followed by biliary and fecal excretion (approx. 90%). Less than 2% is excreted unchanged in urine. Renal elimination of metabolites accounts for about 10%.
Renal (60% as unchanged drug and metabolites) and fecal (40% primarily as metabolites).
Category C
Category C
Antimigraine Agent
Antimigraine Agent